Calcipotriol is a synthetic vitamin D₃ analogue developed for the treatment of psoriasis. It was introduced in the late 1980s to provide the therapeutic benefits of vitamin D while minimizing calcium-related side effects. Research focused on modifying the vitamin D structure to selectively regulate skin cell growth and differentiation. Calcipotriol was found to effectively reduce excessive keratinocyte proliferation seen in psoriatic lesions. Its topical use showed good efficacy with a favorable safety profile. The drug was first approved in Europe and later worldwide. It became widely used as monotherapy or in combination with corticosteroids. Calcipotriol was subsequently included in major pharmacopeias for quality control. Standardized formulations improved consistency and patient compliance. Today, calcipotriol remains a cornerstone in topical psoriasis management.
BRAND NAMES
Dovonex – widely used topical cream/ointment
Daivonex – alternative spelling in some regions
Calcitrene – topical formulation in certain countries
Psorcutan – ointment form in some markets
MECHANISM OF ACTION
Calcipotriol is a vitamin D3 analogue that treats psoriasis by binding to skin cell receptors, slowing excessive keratinocyte growth, promoting normal cell maturation, and reducing local inflammation, with mainly local effects and minimal systemic absorption.
PHARMACOKINETICS
Absorption
Calcipotriol is poorly absorbed through intact skin, with only a small fraction entering systemic circulation. Absorption may increase when applied over large areas, damaged skin, or under occlusion, but overall systemic availability remains low.
Distribution
Calcipotriol shows minimal systemic absorption (<1%), is highly protein bound (~99%), and has a short half-life of about 5–6 hours, resulting in very low bioavailability and mainly localized action in the skin.
Metabolism
Calcipotriol is rapidly metabolized in the liver to inactive metabolites through side-chain modification. This fast metabolism contributes to its low systemic effects and overall safety when used topically.
Excretion
Calcipotriol and its metabolites are primarily excreted via bile into feces, with only a small amount eliminated through urine. This biliary excretion contributes to its low systemic accumulation.
PHARMACODYNAMICS
Calcipotriol is a vitamin D3 analogue that binds to receptors in skin cells to regulate gene expression, reducing keratinocyte proliferation, promoting normal differentiation, and decreasing inflammation, thereby improving psoriatic lesions.
DOSAGE AND ADMINISTRATION
Calcipotriol is applied topically as a thin layer to affected skin once or twice daily, with a recommended maximum of about 100 g per week in adults, and is often used alone or in combination with corticosteroids for better results.
CONTRAINDICATIONS
Calcipotriol is applied topically as a thin layer to affected skin once or twice daily, with a recommended maximum of about 100 g per week in adults, and is often used alone or in combination with corticosteroids for better results.
DRUG INTERACTIONS
Calcipotriol has minimal hypercalcemia, but using it with other vitamin D products or calcium supplements may increase the risk of hypercalcemia, and salicylic acid can reduce its effectiveness.
SIDE EFFECTS
Skin irritation
Itching
Redness
Burning
OVER DOSE
Topical overdose is uncommon but can occur if large areas are treated excessively. It may lead to hypercalcemia, nausea, vomiting, weakness, and kidney problems. Treatment involves discontinuing the drug and providing supportive care to manage calcium levels.
TOXICITY
Calcipotriol toxicity is rare due to minimal systemic absorption. Excessive use can cause hypercalcemia, hypercalciuria, and kidney dysfunction. Local toxicity may present as severe skin irritation, redness, or peeling. Monitoring is advised if applied over large areas or for prolonged periods.
